Schneeweiss-Gleixner, Mathias <br/><br/>
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1  [electronic resource] 

 -  EBioMedicine  Dec 2019 
 - 111-121 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2352-3964 
<br/><br/><label>Standard No.: </label>10.1016/j.ebiom.2019.11.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Apoptosis--drug effects<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cyclin-Dependent Kinase 4--antagonists & inhibitors<br/>Cyclin-Dependent Kinase 6--antagonists & inhibitors<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--genetics<br/>Drug Synergism<br/>Female<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Hydroxyurea--pharmacology<br/>Imidazoles--pharmacology<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--genetics<br/>Male<br/>Middle Aged<br/>Mutation<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyridazines--pharmacology